Declining rates of opioid/acetaminophen combination product overdose : 2011-2020
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Association for the Study of Liver Diseases..
BACKGROUND: During the opioid epidemic, misuse of acetaminophen-opioid products resulted in supratherapeutic acetaminophen ingestions and cases of hepatotoxicity. In 2014, the US Food and Drug Administration (FDA) limited the amount of acetaminophen in combination products to 325 mg, and the US Drug Enforcement Administration (DEA) changed hydrocodone/acetaminophen from schedule III to schedule II. This study assessed whether these federal mandates were associated with changes in acetaminophen-opioid supratherapeutic ingestions.
METHODS: We identified emergency department encounters at our institution of patients with a detectable acetaminophen concentration and manually reviewed these charts.
RESULTS: We found a decline in acetaminophen-opioid supratherapeutic ingestions after 2014. A downtrend in hydrocodone/acetaminophen ingestions accompanied a relative increase in codeine/acetaminophen ingestions from 2015 onwards.
CONCLUSION: This experience at one large safety net hospital suggests a beneficial impact of the FDA ruling in reducing likely unintentional acetaminophen supratherapeutic ingestions, carrying a risk of hepatotoxicity, in the setting of intentional opioid ingestions.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:7 |
---|---|
Enthalten in: |
Hepatology communications - 7(2023), 4 vom: 01. Apr. |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Harris, Elizabeth [VerfasserIn] |
---|
Links: |
---|
Themen: |
362O9ITL9D |
---|
Anmerkungen: |
Date Completed 29.03.2023 Date Revised 06.07.2023 published: Electronic-eCollection Citation Status MEDLINE |
---|
doi: |
10.1097/HC9.0000000000000067 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM354774271 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM354774271 | ||
003 | DE-627 | ||
005 | 20231226062935.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1097/HC9.0000000000000067 |2 doi | |
028 | 5 | 2 | |a pubmed24n1182.xml |
035 | |a (DE-627)NLM354774271 | ||
035 | |a (NLM)36972394 | ||
035 | |a (PII)e0067 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Harris, Elizabeth |e verfasserin |4 aut | |
245 | 1 | 0 | |a Declining rates of opioid/acetaminophen combination product overdose |b 2011-2020 |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 29.03.2023 | ||
500 | |a Date Revised 06.07.2023 | ||
500 | |a published: Electronic-eCollection | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Association for the Study of Liver Diseases. | ||
520 | |a BACKGROUND: During the opioid epidemic, misuse of acetaminophen-opioid products resulted in supratherapeutic acetaminophen ingestions and cases of hepatotoxicity. In 2014, the US Food and Drug Administration (FDA) limited the amount of acetaminophen in combination products to 325 mg, and the US Drug Enforcement Administration (DEA) changed hydrocodone/acetaminophen from schedule III to schedule II. This study assessed whether these federal mandates were associated with changes in acetaminophen-opioid supratherapeutic ingestions | ||
520 | |a METHODS: We identified emergency department encounters at our institution of patients with a detectable acetaminophen concentration and manually reviewed these charts | ||
520 | |a RESULTS: We found a decline in acetaminophen-opioid supratherapeutic ingestions after 2014. A downtrend in hydrocodone/acetaminophen ingestions accompanied a relative increase in codeine/acetaminophen ingestions from 2015 onwards | ||
520 | |a CONCLUSION: This experience at one large safety net hospital suggests a beneficial impact of the FDA ruling in reducing likely unintentional acetaminophen supratherapeutic ingestions, carrying a risk of hepatotoxicity, in the setting of intentional opioid ingestions | ||
650 | 4 | |a Letter | |
650 | 7 | |a Acetaminophen |2 NLM | |
650 | 7 | |a 362O9ITL9D |2 NLM | |
650 | 7 | |a Analgesics, Opioid |2 NLM | |
650 | 7 | |a Hydrocodone |2 NLM | |
650 | 7 | |a 6YKS4Y3WQ7 |2 NLM | |
700 | 1 | |a Harms, Michael |e verfasserin |4 aut | |
700 | 1 | |a Cao, Dazhe |e verfasserin |4 aut | |
700 | 1 | |a Prestwood, Courtney |e verfasserin |4 aut | |
700 | 1 | |a DeBinya, Lister |e verfasserin |4 aut | |
700 | 1 | |a Kleinschmidt, Kurt |e verfasserin |4 aut | |
700 | 1 | |a Young, Amy |e verfasserin |4 aut | |
700 | 1 | |a Saha, Srishti |e verfasserin |4 aut | |
700 | 1 | |a Rule, Jody |e verfasserin |4 aut | |
700 | 1 | |a Alvarez, Kristin |e verfasserin |4 aut | |
700 | 1 | |a Das, Sandeep R |e verfasserin |4 aut | |
700 | 1 | |a Lee, William M |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Hepatology communications |d 2017 |g 7(2023), 4 vom: 01. Apr. |w (DE-627)NLM273051806 |x 2471-254X |7 nnns |
773 | 1 | 8 | |g volume:7 |g year:2023 |g number:4 |g day:01 |g month:04 |
856 | 4 | 0 | |u http://dx.doi.org/10.1097/HC9.0000000000000067 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 7 |j 2023 |e 4 |b 01 |c 04 |